Inib (BMS-354825) is an FDA-approved tiny molecular compound that was developed primarily to treat chronic
Inib (BMS-354825) is an FDA-approved tiny molecular compound that was developed primarily to treat chronic myeloid Nav1.7 MedChemExpress leukemia (CML) as a multi-targeted tyrosine kinase inhibitor against wild-type BCR-ABL and…